ライフサイエンスコーパス: RFA

1 RFA (30 W per 30 second duration) was applied at 5g, 10g

2 RFA and 5-W MWA increased postablation tumor growth rate

3 RFA and cryoablation have each been used for renal tissu

4 RFA and EVLT offer comparable venous occlusion rates at

5 RFA and SBRT groups were similar with respect to number

6 RFA did not reduce mortality or hospitalization for HF d

7 RFA is considered high-risk when the lesion is in close

8 RFA is well tolerated and efficacious in most but not al

9 RFA might be cost effective for confirmed and stable LGD

10 RFA performed during the same procedure after electrophy

11 RFA was associated with a lower hazard for stroke (hazar

12 RFA was performed to ablate the tumor center alone.

13 RFA-SBRT was the preferred strategy, because RFA-RFA and

14 RFA-SBRT yielded 1.558 QALYs and cost $193 288.

15 ween 2002 and 2013, a total of 237 (SR, 109; RFA, 128) patients with BCLC very early-stage HCC were e

16 nts with ARVD/C who underwent a total of 175 RFA procedures between 1992 and 2011 at 80 different ele

17 time point, after a mean of 2.5 (range, 2-6) RFA procedures.

18 rotein subunits of DNA REPLICATION FACTOR A (RFA) were produced.

19 rin during radiofrequency catheter ablation (RFA) of atrial fibrillation is associated with a lower r

20 fficacy of radiofrequency catheter ablation (RFA) of VT in ARVD/C, with particular focus on newer abl

21 effect of radiofrequency catheter ablation (RFA) on reducing morbidity and mortality among patients

22 or without radiofrequency catheter ablation (RFA).

23 term data on renal radio frequency ablation (RFA) and cryoablation confirming their oncologic efficac

24 l approaches, e.g. radio frequency ablation (RFA).

25 e II HCC treated by radiofrequency ablation (RFA) +/- transarterial chemoembolization (TACE) or surgi

26 RECENT FINDINGS: Radiofrequency ablation (RFA) and endoscopic mucosal resection (EMR) are proven w

27 e studies combining radiofrequency ablation (RFA) and endoscopic mucosal resection into a single endo

28 aricose veins using radiofrequency ablation (RFA) and endovenous laser therapy (EVLT) has reported ad

29 blational rim after radiofrequency ablation (RFA) and their role in driving the stimulation of distan

30 Resection and radiofrequency ablation (RFA) are treatment options for hepatocellular carcinoma

31 resection (LR), and radiofrequency ablation (RFA) as initial therapy for early hepatocellular carcino

32 standard irrigated radiofrequency ablation (RFA) during catheter ablation of AF.

33 otherapy (SBRT) and radiofrequency ablation (RFA) for HCC.

34 -touch multibipolar radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) that met the Mil

35 erapy (SBRT) versus radiofrequency ablation (RFA) for patients with inoperable localized hepatocellul

36 Radiofrequency ablation (RFA) from the epicardial space for ventricular arrhythmi

37 Radiofrequency ablation (RFA) has been shown to be an effective treatment for LGD

38 mpared with hepatic radiofrequency ablation (RFA) in an animal model.

39 ility and safety of radiofrequency ablation (RFA) in Barrett's esophagus are highlighted in this revi

40 during left atrial radiofrequency ablation (RFA) in comparison with uninterrupted oral vitamin K ant

41 ysplasia treated by radiofrequency ablation (RFA) in the randomized controlled Ablation of Intestinal

42 use of endobiliary radiofrequency ablation (RFA) in the treatment of malignant disease of the bile d

43 Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique that destroys can

44 Radiofrequency ablation (RFA) is a potentially curative therapy for hepatocellula

45 BACKGROUND & AIMS: Radiofrequency ablation (RFA) is a safe alternative to esophagectomy for patients

46 Radiofrequency ablation (RFA) is an established treatment for dysplastic Barrett'

47 t force (CF) during radiofrequency ablation (RFA) is an important determinant of endocardial lesion s

48 Radiofrequency ablation (RFA) is commonly used to treat Barrett's esophagus (BE).

49 Radiofrequency ablation (RFA) of ventricular tachycardia (VT) can fail because of

50 BACKGROUND & AIMS: Radiofrequency ablation (RFA) reduces the risk of esophageal adenocarcinoma (EAC)

51 cosal resection and radiofrequency ablation (RFA) therapy.

52 nic milieu by using radiofrequency ablation (RFA) to create a quantifiable prothrombotic nidus.

53 lung tumor by using radiofrequency ablation (RFA) with local injection of an immunostimulant, OK-432,

54 ry (CA) injury with radiofrequency ablation (RFA) within the coronary venous system as a function of

55 t: liver resection, radiofrequency ablation (RFA), and liver transplantation.

56 Radiofrequency ablation (RFA), with or without endoscopic resection effectively e

57 ultiple sessions of radiofrequency ablation (RFA).

58 uently treated with radiofrequency ablation (RFA).

59 uently treated with radiofrequency ablation (RFA).

60 rcinoma (HCC) after radiofrequency ablation (RFA).

61 1168 (206 asymptomatic) underwent ablation (RFA group).

62 r thermal ablation (radiofrequency ablation [RFA] or microwave ablation).

63 ) patients and in 8 patients with additional RFA without CA narrowing in any patient.

64 years after treatment was 70% and 53% after RFA and 74% and 46% after SBRT.

65 ablation was successful in 98.5%, and after RFA, no patients developed malignant arrhythmias or VF o

66 ients treated, 448 (76%) were assessed after RFA.

67 s were performed before RFA and 7 days after RFA, and then hearts were removed and atrial thrombi wer

68 s (interquartile range, 264-1623 days) after RFA and 848 days (interquartile range, 322-2355 days) af

69 nce of esophageal adenocarcinoma (EAC) after RFA, factors associated with the development of EAC, and

70 lational phosphorylated STAT3 24 hours after RFA, which was suppressed with S3I-201 (percentage of po

71 ompared the rate of progression of LGD after RFA with endoscopic surveillance alone in routine clinic

72 with persistent intestinal metaplasia after RFA.

73 with persistent intestinal metaplasia after RFA.

74 salvage therapy for local progression after RFA.

75 salvage therapy for local progression after RFA.

76 manageable, but continued surveillance after RFA is essential.

77 determination of poor overall survival after RFA.

78 sess technique effectiveness 4-8 weeks after RFA.

79 ed CEIM and remained BE free at 1 year after RFA had a low risk of BE recurrence.

80 Our novel algorithm, Random Field Aligner (RFA), captures the relationships among the short reads g

81 through use of resonance frequency analysis (RFA) and damping capacity analysis (DCA).

82 In this retrospective analysis, RFA was performed in 1133 consecutive patients (mean age

83 sham procedure (5-W MWA: 16.3 mm +/- 1.1 and RFA: 16.3 mm +/- 0.9 vs sham: 13.6 mm +/- 1.3, P < .01,

84 e) was increased for 5-W MWA (82% +/- 5) and RFA (79% +/- 5), followed by 20-W MWA (65% +/- 2), compa

85 imilar pattern of inputs is seen for CFA and RFA, with RFA receiving smaller proportion of inputs fro

86 Pathologic studies showed that the Dbait and RFA combination strongly enhances DNA damage and coagula

87 vascular density was greater for 5-W MWA and RFA (P < .01 vs 20-W MWA and sham).

88 Lower-energy MWA and RFA also resulted in increased HSP 70 expression and mac

89 and VEGF elevations were seen in 5-W MWA and RFA compared with 20-W MWA and sham (P < .05).

90 t 7 days, hepatic ablations with 5-W MWA and RFA increased distant tumor size compared with 20-W MWA

91 minimally invasive techniques such as PN and RFA in a variety of tumors.

92 sess the association between progression and RFA.

93 Endoscopic mucosal resection and RFA are the cornerstones in the management of dysplasia

94 We proposed that RWA and RFA are part of a second motor area, the rostral motor a

95 nd rostrally located motor area with RWA and RFA as its constituents.

96 oma (HCC) who are eligible for both SBRT and RFA.

97 s were 48% versus 18% (P < 0.001) for SR and RFA groups, respectively.

98 s were 49% versus 24% (P < 0.001) for SR and RFA groups, respectively.

99 representations, the rostral forelimb area (RFA) and caudal forelimb area (CFA), eliciting identical

100 whiskers, called the rostral forelimb area (RFA) and the rostral whisker area (RWA).

101 Only a rostral forelimb area (RFA) has been definitively described, besides few report

102 of rivaroxaban in the setting of left atrial RFA procedures are lacking.

103 ge, 63+/-10 years) who underwent left atrial RFA procedures between February 2012 and May 2013.

104 In patients undergoing left atrial RFA, continuous periprocedural rivaroxaban use seems to

105 SBRT for local progression (SBRT-SBRT), (b) RFA followed by RFA for local progression (RFA-RFA), (c)

106 RFA-SBRT was the preferred strategy, because RFA-RFA and SBRT-RFA were less effective and more costly

107 Based on histology analysis, before RFA, 71% of patients had high-grade dysplasia or esophag

108 ocardiographic studies were performed before RFA and 7 days after RFA, and then hearts were removed a

109 Endoscopic mucosal resection before RFA did not provide any benefit.

110 nderwent endoscopic mucosal resection before RFA.

111 e-daily proton pump inhibitor therapy before RFA increases the incidence of persistent intestinal met

112 Both RFA and SBRT are effective local treatment options for i

113 le, localized HCC who were eligible for both RFA and SBRT to evaluate the cost-effectiveness of the f

114 Unfortunately, both RFA and EMR have limitations that preclude their univers

115 ia trial, we found BE to recur after CEIM by RFA in almost one third of patients with baseline dyspla

116 progression (SBRT-SBRT), (b) RFA followed by RFA for local progression (RFA-RFA), (c) SBRT followed b

117 progression (RFA-RFA), (c) SBRT followed by RFA for local progression (SBRT-RFA), and (d) RFA follow

118 ib fractures that were apparently induced by RFA and MWA had organ injury or damage related to fractu

119 stability related to the values obtained by RFA and DCA devices, which could create disagreements an

120 Of patients with BE treated by RFA, 56% were in complete remission after 24 months.

121 Combined RFA plus S3I-201 reduced systemic distant tumor growth a

122 Although VT recurrences are common, RFA results in a significant reduction in the burden of

123 In contrast, RFA leads to thermal nerve damage, causing protein denat

124 omography-guided radiofrequency ablation (CT-RFA) and laparoscopic RFA (L-RFA) have been used to trea

125 LTP (73.3% vs. 67.9%, p = 0.8897) between CT-RFA and L-RFA.

126 mall HCC abutting the diaphragm, and both CT-RFA and L-RFA are effective techniques.

127 In conclusion, CT-RFA is a relatively easy and economic technique for recu

128 < 0.0001) were significantly lower in the CT-RFA in comparison to that of L-RFA.

129 e HCC nodules and 11-year experience with CT-RFA.

130 FA for local progression (SBRT-RFA), and (d) RFA followed by SBRT for local progression (RFA-SBRT).

131 During RFA, heparin was given intravenously to maintain an acti

132 ational normalized ratio (INR) levels during RFA have not been defined.

133 a therapeutic activated clotting time during RFA was reduced by 50% in patients with an INR>2.0.

134 domly assigned (2:1 ratio) to receive either RFA (entire BE segment ablated circumferentially) or a s

135 rategies for HGD: (1) esophagectomy, (2) EMR-RFA, and (3) endoscopic surveillance.

136 ion followed by radiofrequency ablation (EMR-RFA) for the treatment of Barrett esophagus with high-gr

137 -old patient, compared to esophagectomy, EMR-RFA yields equivalent utility (11.5 vs 11.4 discounted q

138 Dominance of EMR-RFA over esophagectomy persists for all age groups.

139 effectiveness and cost-effectiveness of EMR-RFA versus esophagectomy for HGD remains unclear.

140 may be managed by surgical resection or EMR-RFA.

141 Existing evidence supports EMR-RFA over esophagectomy for the treatment of esophageal H

142 National guidelines suggest that EMR-RFA is effective at eradicating HGD.

143 ch was significantly longer than endocardial RFA (P=0.021).

144 Epicardial RFA for ventricular arrhythmias is often limited even wh

145 Epicardial RFA was impeded in the majority of cases targeting the l

146 and assessed the effect of failed epicardial RFA on outcome after ablation procedures for ventricular

147 ulative freedom from VT following epicardial RFA was 64% and 45% at 1 and 5 years, respectively, whic

148 We assessed reasons for epicardial RFA failure relative to the anatomic target area and the

149 5.0; P<0.001) after no or limited epicardial RFA compared with unlimited RFA, and patients with unlim

150 lesion size with limited data on epicardial RFA and CF.

151 RFA, and patients with unlimited epicardial RFA had better recurrence-free survival rates (P<0.001).

152 After remodeling was established, RFA lesions were created in both atria.

153 Six out of 7 patients had failed RFA attempts (including epicardial in 3).

154 ies were collected 12 months after the first RFA; clearance of HGD, dysplasia, and BE were assessed.

155 he need for continued surveillance following RFA, even after complete eradication of intestinal metap

156 Recurrence of VT following RFA and effect of RFA on the burden of VT were assessed.

157 procedure success rates were 90% and 77% for RFA and cryoablation at the ideal site, respectively.

158 vide major inputs to RWA are the same as for RFA, and the nuclei projecting to CWA are same as for CF

159 ved survival (median, 84 days vs 40 days for RFA alone, P = .0004), with approximately half of the an

160 umors >/= 2 cm, there was decreased FFLP for RFA compared with SBRT (HR, 3.35; P = .025).

161 ld be carefully monitored in preparation for RFA of atrial fibrillation.

162 thus, they were not considered suitable for RFA or microwave ablation.

163 o-pay threshold of $100 000 per QALY gained, RFA-SBRT was preferred in 65.8% of simulations.

164 analysis was performed in mice after hepatic RFA or sham procedure; mice were sacrificed 24 hours to

165 ated in the periablational rim after hepatic RFA, of which STAT3 was active in four of seven.

166 ss off-target tumorigenic effects of hepatic RFA.

167 Next, animals were allocated to hepatic RFA or sham treatment with or without STAT3 (signal tran

168 he Cox proportional hazards model identified RFA as an independent predictor for mortality and tumor

169 energy delivery are the goals of research in RFA and cryoablation.

170 However, incomplete RFA can induce accelerated invasive growth at the periph

171 periphery to mild hyperthermia and increases RFA antitumor efficacy.

172 ute coronary injury with direct and indirect RFA and phrenic nerve palsy occurrence was proportional

173 Initial RFA is more effective and less costly than endoscopic su

174 RFA when HGD was detected (S2), and initial RFA followed by endoscopic surveillance (S3).

175 By using updated data, initial RFA might not be cost effective for patients with BE wit

176 Among patients with HGD, initial RFA was more effective and less costly than endoscopic s

177 oup with HGD, we compared results of initial RFA with endoscopic surveillance with surgery when cance

178 Intraductal RFA, via both endoscopic and percutaneous approaches, is

179 In 12 sheep, a 7-F irrigated RFA catheter with CF sensor was introduced via a pericar

180 evaluated CF characteristics using irrigated RFA on the epicardium in an ovine model.

181 butting the diaphragm, and both CT-RFA and L-RFA are effective techniques.

182 vs. 67.9%, p = 0.8897) between CT-RFA and L-RFA.

183 wer in the CT-RFA in comparison to that of L-RFA.

184 cy ablation (CT-RFA) and laparoscopic RFA (L-RFA) have been used to treat intrahepatic recurrent smal

185 frequency ablation (CT-RFA) and laparoscopic RFA (L-RFA) have been used to treat intrahepatic recurre

186 Conclusion No-touch multibipolar RFA for HCC tumors that meet Milan criteria provides a h

187 eria were treated with no-touch multibipolar RFA, which consisted of activating, in bipolar mode, thr

188 y 2007 through July 2011 from US multicenter RFA Patient Registry.

189 1 (550 asymptomatic) did not undergo RFA (no-RFA group) and 1168 (206 asymptomatic) underwent ablatio

190 In the no-RFA group, VF occurred in 1.5% of patients, virtually ex

191 + complications occurred after 11% and 5% of RFA and SBRT treatments, respectively (P = .31).

192 Connections of RFA, CFA, and the caudally located hindlimb area (CHA),

193 were grouped based on the INR on the day of RFA.

194 urther supported by the inhibitory effect of RFA expression on the cell-to-cell movement of Bean dwar

195 Recurrence of VT following RFA and effect of RFA on the burden of VT were assessed.

196 the effectiveness and cost effectiveness of RFA for the management of BE.

197 New data on the cost-effectiveness of RFA have also been published, suggesting that RFA is cos

198 of case volume on the safety and efficacy of RFA or about the presence or contour of learning curves

199 The expression of RFA-tagged proteins is regulated by the simple folate an

200 l centers on safety and efficacy outcomes of RFA.

201 ging data on the effectiveness and safety of RFA, recurrence and progression of disease remain an iss

202 val (LTPFS) were calculated from the time of RFA by using the Kaplan-Meier method.

203 zed case series have now reported the use of RFA in mixed cohorts of human individuals with pancreati

204 10 minutes, simulating the marginal zone of RFA treatment.

205 ure; patients in the sham group were offered RFA treatment 1 year later, and all patients were follow

206 ion was 163 patients treated with MWA and/or RFA for 195 lung neoplasms between February 2004 and Apr

207 etween patients initially treated with SR or RFA (P = 0.415).

208 udy of PV isolation using either the VGLB or RFA (control).

209 sent in 13.5% of patients after percutaneous RFA and MWA of lung neoplasms.

210 ents with 233 CLMs treated with percutaneous RFA between December 2002 and December 2012.

211 cted to atrial tachypacing during 7-day post-RFA follow-up.

212 atrial tachycardia/AF itself, enhanced post-RFA atrial thrombus formation.

213 d structural remodeling did not predict post-RFA thrombogenic potential.

214 for all arms: 0.60-0.64 mm/d; postablation: RFA: 0.91 mm/d +/- 0.11, 5-W MWA: 0.91 mm/d +/- 0.14, P

215 ) RFA followed by RFA for local progression (RFA-RFA), (c) SBRT followed by RFA for local progression

216 RFA followed by SBRT for local progression (RFA-SBRT).

217 same enrollment criteria but did not receive RFA were matched (</=1:20) by hospitals and dates to ser

218 nts in the AIM Dysplasia trial, 119 received RFA and met inclusion criteria.

219 ss-over subjects were included, 119 received RFA.

220 A total of 846 patients with AF who received RFA and 11 324 matched AF controls were included, with a

221 We followed patients who received RFA for BE containing high-grade intraepithelial neoplas

222 e analysis had been made in various regions; RFA and DCA should have been applied in the same implant

223 own of native carbon in raw fly ash samples (RFA) and for the formation and destruction of polychlori

224 preferred strategy, because RFA-RFA and SBRT-RFA were less effective and more costly.

225 followed by RFA for local progression (SBRT-RFA), and (d) RFA followed by SBRT for local progression

226 e lesions (n = 40 [72%]), followed by serial RFA every 3 months.

227 rett's esophagus neoplasia, and a simplified RFA algorithm.

228 Since RFA and resection are not options given tumor location,

229 Although epicardial fat limits lesion size, RFA with high CF can produce small myocardial RF lesions

230 Sublethal RFA or Dbait treatment alone moderately improved surviva

231 treated with Dbait alone (n = 20), sublethal RFA (n = 21), three different Dbait schemes and subletha

232 three different Dbait schemes and sublethal RFA (n = 52), or a sham treatment (n = 18).

233 Suboptimal RFA accelerates HCC growth and spread by transiently ind

234 dicted the recurrence of IM after successful RFA.

235 Targeted RFA with a newly developed articulating device is both f

236 copic or computed tomography-guided targeted RFA was performed in 26 patients (47 tumors) with painfu

237 We test RFA through extensive simulations and apply it to discov

238 We demonstrate that RFA facilitates accurate recovery of variation in 155 Mb

239 eradicating dysplasia, most have found that RFA is not as effective in eradicating intestinal metapl

240 Although some studies have indicated that RFA is effective at eradicating dysplasia, most have fou

241 The observation that RFA complex plants dramatically inhibited the transient

242 FA have also been published, suggesting that RFA is cost-effective for both high-grade and low-grade

243 The RFA tag should facilitate study of the role of essential

244 In the RFA group, ablation was successful in 98.5%, and after R

245 % in the surveillance group and 0.77% in the RFA group.

246 n is correct, we selectively inactivated the RFA/grasp area during the performance of skilled forelim

247 Overexpression of the RFA complex in tobacco resulted in decreased T-DNA expre

248 observed during cooling deactivation of the RFA/grasp area, but not the CFA/arm area.

249 The mechanisms underlying the RFA-induced tumor promotion remain largely unexplored.

250 using a flow-over solid system in which the RFA samples were thermally treated at 300 degrees C unde

251 3230 adenocarcinoma tumors were allocated to RFA or sham treatment with or without a STAT3 inhibitor

252 dioembolization is a possible alternative to RFA in such cases.

253 egmentectomy in solitary HCC not amenable to RFA or resection.

254 table, solitary HCC </= 5 cm not amenable to RFA were included in this multicenter study.

255 benefit of liver transplantation compared to RFA +/- TACE was 1.5 months at 3 years (range -3.5 to 5.

256 we showed that sources of thalamic inputs to RFA and RWA are similar, but they are different from tho

257 Sources of inputs to RFA, caudal forelimb area (CFA), and caudal hindlimb reg

258 icacy of VGLB ablation proved noninferior to RFA for the treatment of paroxysmal AF.

259 oing endovenous treatment were randomized to RFA (VNUS ClosureFAST) or EVLT (810-nm diode laser).

260 ive, at $558 679 per QALY gained relative to RFA-SBRT.

261 nd increased distant tumor growth similar to RFA in an animal tumor model, higher-power, faster heati

262 nts, 1001 (550 asymptomatic) did not undergo RFA (no-RFA group) and 1168 (206 asymptomatic) underwent

263 or patients with early-stage HCC who undergo RFA.

264 comes of patients with BE who have undergone RFA for neoplasia.

265 Among patients who have undergone RFA with or without endoscopic resection for neoplastic

266 Thirty-seven patients with BE underwent RFA, high-resolution manometry, and 24-hour impedance-pH

267 ctive study of patients who either underwent RFA (n = 45) or surveillance endoscopy (n = 125) for LGD

268 he Milan criteria who subsequently underwent RFA from 2002 to 2013.

269 l resection, and the patients then underwent RFA every 3 months until all areas of BE were ablated or

270 r stroke or heart failure (HF) who underwent RFA between 2003 and 2009 was identified using Taiwan's

271 data for outcomes of patients who underwent RFA for BE from July 2007 through July 2011 from US mult

272 148 institutions) for patients who underwent RFA for BE from July 2007 to July 2011.

273 patients in the United Kingdom who underwent RFA for BE-related neoplasia and found that by 12 months

274 lticenter registry of patients who underwent RFA of BE, less than 1% died from EAC.

275 ificantly lower among patients who underwent RFA than those who underwent surveillance (adjusted haza

276 mited epicardial RFA compared with unlimited RFA, and patients with unlimited epicardial RFA had bett

277 We collected data from the US RFA Patient Registry (from 148 institutions) for patient

278 d self-expanding metal stent clearance using RFA have been published.

279 feasible as a bail-out approach to failed VT RFA, particularly those originating from the left ventri

280 n alternative bail-out approach to failed VT RFA.

281 1 of 22 (50%) and 1 of 15 (7%) patients when RFA was performed within 2 and 3 to 5 mm of a CA, respec

282 first-line curative treatments, among which RFA provided the best value for money.

283 t 7 days (end diameter: 11.8 mm +/- 0.5 with RFA plus S3I-201, 19.8 mm +/- 0.7 with RFA alone, and 15

284 with RFA plus S3I-201, 19.8 mm +/- 0.7 with RFA alone, and 15 mm +/- 0.7 with sham procedure; P < .0

285 effect on stroke prevention associated with RFA was suggested, residual confounding attributable to

286 No deaths were associated with RFA.

287 es better long-term OS and RFS compared with RFA in patients with BCLC very early-stage HCC.

288 ociated with better OS and RFS compared with RFA; the 5-year OS rates were 80% versus 66% (P = 0.034)

289 Combining Dbait with RFA sensitizes the tumor periphery to mild hyperthermia

290 The risk of CA injury with RFA is correlated inversely with the distance from the a

291 , 3 of whom were successfully reablated with RFA.

292 tern of inputs is seen for CFA and RFA, with RFA receiving smaller proportion of inputs from the fore

293 detected (S1), endoscopic surveillance with RFA when HGD was detected (S2), and initial RFA followed

294 normal non-tumor-bearing liver treated with RFA (70 degrees C x 5 minutes), rapid higher-power MWA (

295 predicted for FFLP in patients treated with RFA (hazard ratio [HR], 1.54 per cm; P = .006), but not

296 eoplasia in 3 patients who were treated with RFA for Barrett's esophagus (2 developed adenocarcinoma

297 data from 592 patients with BE treated with RFA from 2003 through 2011 at 3 tertiary referral center

298 and EAC were lower among those treated with RFA than among untreated patients.

299 One- and 2-year FFLP for tumors treated with RFA were 83.6% and 80.2% v 97.4% and 83.8% for SBRT.

300 s developed in 6.5% of subjects treated with RFA; strictures were the most common complication.